EA201992186A1 - Антитела к par2 и пути их применения - Google Patents
Антитела к par2 и пути их примененияInfo
- Publication number
- EA201992186A1 EA201992186A1 EA201992186A EA201992186A EA201992186A1 EA 201992186 A1 EA201992186 A1 EA 201992186A1 EA 201992186 A EA201992186 A EA 201992186A EA 201992186 A EA201992186 A EA 201992186A EA 201992186 A1 EA201992186 A1 EA 201992186A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- par2
- antibodies
- ways
- application
- antigen binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
В настоящем изобретении предусмотрены антитела и антигенсвязывающие фрагменты, способные связывать PAR2. В некоторых вариантах осуществления антитела к PAR2 или их антигенсвязывающие фрагменты связывают PAR2 зависимым от pH образом. В настоящем изобретении дополнительно предусмотрены способы получения и применения антител и антигенсвязывающих фрагментов.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862637766P | 2018-03-02 | 2018-03-02 | |
PCT/EP2018/056776 WO2018167322A1 (en) | 2017-03-16 | 2018-03-16 | Anti-par2 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201992186A1 true EA201992186A1 (ru) | 2020-03-05 |
Family
ID=69942789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992186A EA201992186A1 (ru) | 2018-03-02 | 2018-03-16 | Антитела к par2 и пути их применения |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA201992186A1 (ru) |
-
2018
- 2018-03-16 EA EA201992186A patent/EA201992186A1/ru unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202092847A1 (ru) | Антитела к cd3 и их применение | |
CY1124384T1 (el) | Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3 | |
MX2022003718A (es) | Anticuerpos que se unen a cd39 y sus usos. | |
EA201891582A1 (ru) | Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки | |
BR112018067458A2 (pt) | anticorpos para tigit | |
JOP20160131B1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
EA201692504A1 (ru) | Триспецифичные связывающие молекулы и способы их применения | |
PH12019502087A1 (en) | Anti-par2 antibodies and uses thereof | |
MX2018007630A (es) | Anticuerpos contra la metaloproteinasa de matriz 9. | |
EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
PH12014501931A1 (en) | Antibodies to matrix metalloproteinase 9 | |
EA202090559A1 (ru) | Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение | |
EA202091350A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
EA201992281A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
MX2022009915A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
EA201990895A1 (ru) | Антитела к о1 и варианты их применения | |
EA202190235A1 (ru) | Антитела к cd33 и способы их применения | |
EA202092085A1 (ru) | ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ | |
EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
CL2023001064A1 (es) | Proteína de unión al antígeno anti-steap1 | |
MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
ATE552266T1 (de) | Modifizierte hiv-1-hüllproteine | |
MX2016011177A (es) | Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos. |